This in vitro study evaluated whether combining gepotidacin with other antimicrobials alters its activity against reference isolates of Neisseria gonorrhoeae. The investigation focused on combination effects determined by checkerboard testing, aiming to identify potential synergistic, additive, or antagonistic interactions that could inform future therapeutic strategies or further research.
Testing was performed on six WHO N. gonorrhoeae reference strains and quality-control strain ATCC 49226. Combination susceptibility was assessed using checkerboard assays prepared in Graver-Wade broth. Interaction interpretation used standard fractional inhibitory concentration (FIC) calculations for each agent and the fractional inhibitory concentration index (FICI) for each drug pair.
The abstract reports the experimental framework—strains, medium, and the checkerboard approach—but does not provide detailed step-by-step laboratory procedures, incubation conditions, inoculum densities, or exact MIC endpoints in the published abstract.
Gepotidacin was combined individually with the following comparator agents: azithromycin, cefixime, ceftriaxone, gemifloxacin, sitafloxacin, gentamicin, spectinomycin, doxycycline, and lefamulin. These agents represent a range of drug classes and agents previously used or considered for gonorrhea treatment.
Interaction outcomes were evaluated using two related metrics reported in the abstract:
Individual FIC values: the fractional inhibitory concentration of each drug in the pair, calculated relative to its standalone MIC when used in combination wells.
FICI (FIC index): the sum of the two FIC values for a combination, used to categorize interactions as synergistic, additive/indifferent, or antagonistic according to standard interpretive criteria.
The authors reported results based on these measures; the abstract specifies overall findings but does not list the numeric thresholds used for categorization or the exact FIC/FICI values for specific strain–agent combinations.
According to the abstract, evaluation of the FICI for gepotidacin combined with each comparator agent showed no synergistic or antagonistic interactions across the tested panel. In other words, no combinations reached FICI-defined synergy or antagonism when considering the combined index for each drug pair.
However, assessment of the individual FIC values revealed that some combinations produced strain- and agent-specific synergistic or additive effects. This indicates heterogeneity in how particular isolates responded to certain gepotidacin partner drugs, even though the summed FICI did not indicate synergy or antagonism on a combination-wide basis.
The abstract does not include the specific strain–agent pairings that yielded individual FIC-based synergy or additivity, nor does it provide numerical MIC, FIC, or FICI values. Detailed pairwise results and the number of isolates showing each interaction category are therefore not reported in the source abstract.
The abstract conveys the study design and high-level outcomes but omits key detailed data that would be required to fully interpret clinical or laboratory implications. Specifically not reported in the abstract are:
Because these details are not included in the abstract, readers seeking numeric results or to evaluate the robustness of observed strain-specific effects should consult the full text.
Authors are affiliated with Laboratory Specialists, Inc. (L.M. Koeth and J. DiFranco-Franco) and the GSK Infectious Diseases Research Unit (J. West and N.E. Scangarella-Oman). The abstract discloses that Laboratory Specialists, Inc. received financial support from GSK for study conduct and manuscript preparation. Two authors (N.E.S.-O. and J.W.) are employees of GSK. These conflicts of interest are stated in the source.
The study appears in Antimicrobial Agents and Chemotherapy, citation: 2026 Aug 5;70(8):e0005926. DOI 10.1128/aac.00059-26. PubMed ID 42390436. Keywords listed in the abstract include N. gonorrhoeae, antibacterial agent, antimicrobial susceptibility testing, checkerboard assay, and gepotidacin.
The abstract indicates that, by FICI criteria, combining gepotidacin with the tested agents did not produce general synergy or antagonism, but that isolate-specific additive or synergistic signals were observed when individual FICs were examined. These findings suggest heterogeneity across strains and partner drugs and highlight the need to review the full dataset to understand which pairings and isolates showed potential benefit. Clinical implications cannot be inferred from the abstract alone; additional data from the full text and in vivo or clinical studies would be required to guide therapeutic recommendations.